|
|
| |
|
HARDWARE AND SOFTWARE SPECIFICATIONS NEEDED TO VIEW SITE
This course requires Windows Operating Systems (95/98, NT, 2000, ME, XP), version 5.5 browsers or higher from Microsoft or Netscape.
Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
|
| |
|
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Excerpta Medica, Inc. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.
|
| |
|
CREDIT DESIGNATION STATEMENT
The EOCME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
| |
|
DISCLOSURES
As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty of this CME activity disclose the following:
|
Faculty Member
|
|
Manufacturer
|
|
Relationship
|
| Samuel Z. Goldhaber, MD |
|
Boehringer-Ingelheim, Bristol-Myers Squibb, Eisai, sanofi-aventis |
|
Grant/Research Support |
| |
|
Boehringer-Ingelheim, Bristol-Myers Squibb, Eisai, Merck, Pfizer, sanofi-aventis |
|
Consultant |
| Deepak L. Bhatt, MD |
|
Bristol-Myers Squibb, sanofi-aventis U.S., The Medicines Company |
|
Speaker’s Bureau |
| |
|
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Eisai, GlaxoSmithKline, Millennium, ParinGenix, Protein Design Labs, sanofi-aventis U.S., Schering-Plough, The Medicines Company |
|
Consultant/Advisory Board |
| Geno J. Merli, MD |
|
sanofi-aventis U.S., AstraZeneca |
|
Grants/Research Support, Consultant, Speaker’s Bureau |
| |
|
Bacchus Vascular, Inc. |
|
Consultant |
| |
|
Bayer Pharmaceuticals Corporation |
|
Grants/Research Support |
| Activity Director |
|
|
|
|
| Paul Ruest, PhD |
|
Excerpta Medica |
|
Nothing to Disclose |
| Jennifer DiBenedetto, EdM |
|
EOCME |
|
Nothing to Disclose |
|
| |
|
RESOLUTION OF CONFLICT OF INTEREST
The EOCME has implemented a process to resolve conflicts of interest for each CME activity. In order to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public, the EOCME has resolved the conflict by conducting peer review.
|
| |
|
UNAPPROVED/OFF-LABEL USE DISCLOSURE
The EOCME requires CME faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
|
| |
|
INTENDED AUDIENCE
This activity is being developed for clinicians involved in the treatment and prophylaxis of thromboembolic disease.
|
| |
|
PROGRAM GOAL
The goal of this activity is to introduce and provide data on current issues associated with management of thromboembolic disease with warfarin.
|
| |
|
EDUCATIONAL OBJECTIVES
After completing this educational activity and the post-test, participants should be able to:
- Discuss the importance of correct warfarin dosing for optimal venous thromboembolism (VTE) treatment and prophylaxis
- Identify the most appropriate duration of warfarin therapy based on a given patient’s risk profile
- Identify commonly encountered barriers that must be overcome in order to provide optimal anticoagulation therapy with warfarin
- Discuss the improved ways of utilizing warfarin, including centralized anticoagulation clinics, point-of-care testing, and pharmacogenetic testing
- Describe the findings of recent pharmacogenetic research on optimal warfarin management and understand how these data are currently being translated to clinical practice
- Explain the overall importance of optimal warfarin dosing, duration of therapy, and use of concomitant medications
|
| |
|
FINANCIAL SUPPORT
This CME activity is supported by an educational grant from sanofi-aventis U.S.
|
| |
|
CME PLANNING COMMITTEE
Samuel Z. Goldhaber, MD
Deepak L. Bhatt, MD
Geno J. Merli, MD
Paul Ruest, PhD
Jennifer DiBenedetto, EdM
|
| |
|
SPECIAL NEEDS
We encourage participation by all individuals. If you have any special needs, please contact Kelly Kramer at (908) 547-2182, or k.kramer@elsevier.com for assistance.
|